REG - Reckitt Benckiser Gp - Reckitt Q3 2025 Trading Update
Wed 07:00
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251022:nRSV2911Ea&default-theme=true
RNS Number : 2911E Reckitt Benckiser Group PLC 22 October 2025
22 October 2025
Q3 Results 2025
CONTINUED DELIVERY, EXECUTING ON OUR PLAN
"We have delivered a strong third-quarter performance with LFL net revenue up
6.7% in Core Reckitt. These results reflect sequential volume improvements and
the strength of our Powerbrands. We returned to growth in Developed Markets
against a challenging consumer landscape and continued to deliver outsized
growth in Emerging Markets. With our sharpened operating structure, we are
executing our plan and progressing our strategic objectives to be a
world-class consumer health and hygiene company. We are pleased with our
performance and we are confident in delivering our full year 2025 guidance."
Kris Licht, Chief Executive Officer
Q3 2025 YTD 2025
Net Revenue £m LFL(1) IFRS £m LFL1 IFRS
Emerging Markets 1,080 +15.5% +11.8% 3,159 +13.7% +8.5%
Europe 865 +0.8% +0.9% 2,554 -0.3% -2.6%
North America 658 +1.3% -2.5% 1,896 -0.7% -3.8%
Core Reckitt 2,603 +6.7% +4.2% 7,609 +5.0% +1.4%
Essential Home 479 -4.9% -6.4% 1,390 -6.0% -9.0%
Mead Johnson Nutrition 529 +22.0% +18.9% 1,592 +4.0% 0.0%
Group 3,611 +7.0% +4.5% 10,591 +3.3% -0.3%
1. Adjusted and Non-GAAP measures are defined on page 8.
Group
Net Revenue £m Volume Price / Mix LFL(1) Net M&A FX IFRS
Q3 2025 3,611 +4.2 % +2.8% +7.0% -0.1% -2.4% +4.5%
Net Revenue £m Volume Price / Mix LFL(1) Net M&A FX IFRS
YTD 2025 10,591 +0.7% +2.6% +3.3% 0.0% -3.6% -0.3%
1. Adjusted and Non-GAAP measures are defined on page 8.
q3 highlights
Strong Group performance driven by Core Reckitt
· Core Reckitt Q3 LFL net revenue growth +6.7% (YTD: +5.0%), led by
stand-out growth in Emerging Markets and a return to growth in North America
and Europe.
· Volume growth momentum in Core Reckitt continues, Q3 LFL net revenue
comprised +3.4% volume growth (versus +1.2% in H1) and a well-balanced
algorithm with +3.3% price/mix contribution.
· Group Q3 LFL net revenue growth +7.0% (YTD: +3.3%), driven by Core
Reckitt and supported by Mead Johnson Nutrition (LFL net revenue +22.0%) as
the business lapped the significant impact of the July 2024 tornado (Nutrition
Q3 2024 LFL net revenue -17.4%). Essential Home Q3 LFL net revenue growth of
-4.9% (YTD -6.0%).
Volume-led momentum in Core Reckitt with all Areas in growth
· Further broad-based growth across Emerging Markets regions and
categories; LFL net revenue +15.5% in Q3 (+13.7% YTD), led by sustained
outperformance in China and with a balanced contribution across volume (+7.4%)
and price / mix (+8.1%).
· Europe returned to growth in Q3, LFL net revenue growth of +0.8%
(-0.3% YTD), with recent innovations driving positive mix through
premiumisation and sequential volume improvement despite a challenging
consumer backdrop.
· North America produced a solid performance outside of seasonal OTC
in Q3, returning to LFL net revenue growth of +1.3% (YTD -0.7%) despite
lapping a Covid spike in Q3 2024.
· Categories delivering volume and LFL net revenue growth in Q3, led
by Intimate Wellness and Germ Protection, driven by category-creating
innovations. All categories in growth through 2025 YTD.
Delivering our strategy
· Delivering a balanced growth algorithm, with volume and price / mix
performance benefiting from recent innovations including across Self Care
(Mucinex Rapid+Clear and Childrens medicated Mighty Chews) and Intimate
Wellness (Durex Intensity, upgrades to Benzocaine condoms and lubricants
portfolio in China).
· Continued progress towards completion of the announced divestment
of Essential Home; transaction expected to complete by 31 December 2025.
· £1 billion share buyback programme commenced on 28 July 2025. As of
21 October 2025 the first £250m tranche has been completed.
FY 2025 outlook MAINTAINED
· FY 2025 outlook maintained; we expect LFL net revenue growth
above 4% in Core Reckitt.
· Maintained expectations for Mead Johnson Nutrition at low-to-mid
single digit LFL net revenue growth in FY 2025.
· In Essential Home, we expect a mid single digit decline in LFL net
revenue for FY 2025 (from low single digit decline previously).
· Overall, for FY 2025, we maintain expectations of Group LFL net
revenue growth of +3% to +4%.
· Our Fuel for Growth programme is expected to help drive adjusted
operating profit ahead of net revenue growth.
· We expect to deliver another year of adjusted diluted EPS growth.
· Other technical guidance:
o Adjusted net finance expense is expected to be in the range of £350m to
£370m (2024: £323m).
o The adjusted effective tax rate is expected to be around 25% (2024: 22.2%)
o Capital expenditure as a percentage of net revenue is expected to be 3% to
4% (2024: 3.3%).
CORE RECKITT performance
Q3 2025 Net revenue (£m) Volume Price / Mix LFL(1) Net M&A FX IFRS
Emerging Markets 1,080 +7.4% +8.1% +15.5% 0.0% -3.7 % +11.8%
Europe / ANZ 865 -0.5% +1.3% +0.8% -0.4% +0.5% +0.9%
North America 658 +2.3% -1.0% +1.3% 0.0% -3.8 % -2.5%
Core Reckitt 2,603 +3.4% +3.3% +6.7% -0.1% -2.4% +4.2%
YTD 2025 Net revenue (£m) Volume Price / Mix LFL(1) Net M&A FX IFRS
Emerging Markets 3,159 +7.2% +6.5% +13.7% -0.5% -4.7% +8.5%
Europe / ANZ 2,554 -2.4% +2.1% -0.3% -0.2% -2.1% -2.6%
North America 1,896 -0.1% -0.6% -0.7% 0.0% -3.1% -3.8%
Core Reckitt 7,609 +1.9% +3.1% +5.0% -0.3% -3.3% +1.4%
1. Adjusted and Non-GAAP measures are defined on page 8.
Emerging Markets (42% of Core Reckitt Q3 net revenues)
· Emerging Markets net revenue grew +15.5% on a LFL basis in the
quarter to £1,080m, with +7.4% volume growth and +8.1% price / mix
improvement.
· We delivered broad-based growth across our regions in Emerging
Markets with all categories delivering growth in Q3, including Intimate
Wellness and Self Care delivering strong, double-digit growth rates.
· China delivered another strong quarter of broad-based double-digit
growth across categories, with continued success of recently launched new
segments in China, notably Dettol (Botantical fragrances), Durex (Benzocaine
condoms, lubricants upgrades) and Intima (Formula upgrade, Travel pack).
· We continued to drive encouraging sell out performance in India
whilst LFL net revenue growth (low single digit) was impacted by the GST
regime change in September. This resulted in a shift of trade orders to Q4.
LFL net revenue growth in India remains high single digit through 2025 YTD.
· Performance was mixed across Latin America, with a softer
consumer environment in Brazil offset by growth across all categories in
Mexico.
· Double-digit growth was delivered in a number of currently small,
but high potential markets, including Indonesia, Malaysia and Colombia.
· We continued to gain market share across key Germ Protection and
Intimate Wellness category markets, particularly in Dettol (China), Durex
(China and India), Veet (China), and in Self Care; VMS (China) and Gaviscon
(ASEAN and Latin America).
· YTD Emerging Markets net revenue grew +13.7% on a LFL basis.
Europe (33% of Core Reckitt Q3 net revenues)
· Europe net revenue grew +0.8% on a LFL basis in the quarter to
£865m, with -0.5% volume decline and +1.3% price / mix improvement. We have
delivered continued sequential improvement in volumes (Q1 -4.7%, Q2 -1.9%).
· Market-wide category growth remained challenged through Q3 with
broadly flat value growth across the Area.
· Across Europe, four out of our six regions were in LFL net revenue
growth in Q3, with a very challenging pricing environment in Western Europe.
· In Intimate Wellness, we delivered mid single digit growth in
Durex, driven by innovation and the launch of Durex Intensity across a number
of markets, and we are continuing the roll-out of Intensity in Q4 2025.
· Non-seasonal Self Care performed strongly, driven by the continued
success of Gaviscon and Nurofen (including the launch of Nurofen mini liquid
capsules) across a number of markets.
· While Household Care was negatively impacted by a more competitive
pricing environment, we continued to premiumise our consumer offer in Finish,
with strong volume growth of Ultimate Plus in Q3.
· YTD Europe net revenue declined -0.3% on a LFL basis.
North America (25% of Core Reckitt Q3 net revenues)
· North America net revenue grew +1.3% on a LFL basis in the quarter
to £658m, with +2.3% volume growth and -1.0% price / mix decline.
· Outside of our seasonal OTC brands we delivered mid single digit
LFL net revenue growth in Q3.
· Non-seasonal growth was driven by Lysol's positive momentum across
its broadened portfolio (including Lysol Air Sanitiser and Laundry Sanitiser
extensions) and core disinefection segments, a resilient performance in
Finish, and a good performance in Neuriva.
· In seasonal OTC brands, predominantly Mucinex and Delsym, LFL net
revenue declined mid single digit due to double-digit category declines as the
category lapped a Covid spike in Q3 2024.
· The Mucinex Sinus PE-free formulation we transitioned landed as
anticipated, positioning the brand well for the upcoming cold and flu season.
· YTD North America net revenue declined -0.7% on a LFL basis.
Q3 2025 Net revenue Volume Price / Mix LFL (1) Net M&A FX IFRS
(£m)
Self-Care 859 +1.2% +4.4% +5.6% 0.0% -1.7% 3.9%
Germ Protection 838 +8.2% +1.0% +9.2% 0.0% -4.6% +4.6%
Household Care 531 0.0% +0.2% +0.2% 0.0% -0.2% 0.0%
Intimate Wellness 375 +2.6% +10.9% +13.5% -1.0% -1.9% +10.6%
Core Reckitt 2,603 +3.4% +3.3% +6.7% -0.1% -2.4% +4.2%
YTD 2025 Net revenue Volume Price / Mix LFL (1) Net M&A FX IFRS
(£m)
Self-Care 2,412 -3.0% +3.8% +0.8% -0.5% -2.6% -2.3%
Germ Protection 2,414 +7.1% +1.3% +8.4% 0.0% -4.3% +4.1%
Household Care 1,634 -0.3% +1.5 % +1.2% 0.0% -3.2% -2.0%
Intimate Wellness 1,149 +5.6% +7.9% +13.5% -0.7% -3.0% +9.8%
Core Reckitt 7,609 +1.9% +3.1% +5.0% -0.3% -3.3% +1.4%
1. Adjusted and Non-GAAP measures are defined on page 8.
Core Reckitt (72% of Group Q3 net revenue)
· Self Care
o Net revenue grew +5.6% on a LFL basis to £859m in the quarter, with volume
of +1.2% and price / mix of +4.4%.
o Excluding seasonal OTC, Self Care delivered net revenue growth +12.3% on a
LFL basis in the quarter, led by strong growth in our VMS portfolio,
particularly in China, and supported by Gaviscon activation and positive
Nurofen shipment phasing in Europe.
o Seasonal OTC brands (including Mucinex and Strepsils) declined -3.4% on a
LFL basis in Q3, predominantly in North America as we lapped a Covid spike in
Q3 2024.
o YTD Self Care net revenue grew by +0.8% on a LFL basis, with growth of +6.5%
excluding seasonal OTC. Seasonal OTC declined -7.8%.
· Germ Protection
o Net revenue grew +9.2% on a LFL basis to £838m in the quarter, with volume
of +8.2% and price / mix of +1.0%.
o Dettol grew double-digit in the quarter, with strong Emerging Markets
volume-led growth particularly in China (driven by innovation launches and go
to market excellence), India and our Middle East, North Africa, Russia and
Pakistan region ("MENARP").
o Lysol delivered high single digit volume-led growth in North America
including Lysol Laundry Sanitiser and Lysol Air Sanitiser continuing to expand
the brand.
o Harpic's performance was flat in Q3, with growth across Emerging Markets
(predominantly in the brand's largest market of India) while LFL net revenue
declined in Europe.
o YTD Germ Protection net revenue grew by +8.4% on a LFL basis.
· Household Care
o Net revenue grew +0.2% on a LFL basis to £531m in the quarter, with volume
of 0.0% and price / mix of +0.2%.
o Finish grew low single digit in Q3 within Emerging Markets (growth was
strongest in our MENARP region), with a resilient performance in North America
offset by a more challenging environment in Europe.
o In Vanish, Emerging Markets grew mid single digit with a mid single digit
decline in Europe.
o YTD Household Care net revenue grew by +1.2% on a LFL basis.
· Intimate Wellness
o Net revenue grew +13.5% on a LFL basis to £375m in the quarter, with volume
of +2.6% and price / mix of +10.9%.
o Durex grew strongly across Emerging Markets, led by China where the strength
of the brand and recent innovations have continued to drive positive price /
mix and share gains. Durex also grew strongly in ASEAN and MENARP, with the
GST regime implementation in India tempering sell in growth in Q3.
o In Europe, Durex growth accelerated to mid single digit in Q3 with the
launch of Durex Intensity across a number of markets driving overall category
share growth.
o Veet grew strongly in China and MENARP in the quarter in Emerging Markets,
with mid single digit growth across Europe.
o Intima has continued to resonate strongly with Chinese consumers and
delivered another quarter of very strong growth, with the brand more than
doubling LFL net revenue in 2025 YTD.
o YTD Intimate Wellness net revenue grew by +13.5% on a LFL basis.
non-Core segments
Mead Johnson
Nutrition
(15% of Group Q3 net revenue)
Net Revenue £m Volume Price / Mix LFL(1) Net M&A FX IFRS
Q3 2025 529 +12.4% +9.6% +22.0% -0.5% -2.6% +18.9%
Net Revenue £m Volume Price / Mix LFL(1) Net M&A FX IFRS
YTD 2025 1,592 -1.6% +5.6% +4.0% +0.2% -4.2% 0.0%
Mead Johnson Nutrition
· Net revenue grew +22.0% on a LFL basis to £529m in the quarter,
with volume increase of +12.4% and price / mix of +9.6%.
· Q3 net revenue last year was significantly impacted by the Mount
Vernon tornado which destroyed Mead Johnson's primary U.S. warehouse on 9 July
2024.
· In Q3 2025, alongside the recovery in the North American
business, Mead Johnson's international business grew low single digit.
· For 2025 YTD Mead Johnson Nutrition net revenue grew +4.0% on a
LFL basis.
Essential
Home
(13% of Group Q3 net revenue)
Net Revenue £m Volume Price / Mix LFL(1) Net M&A FX IFRS
Q3 2025 479 +0.6% -5.5% -4.9% +0.3% -1.8% -6.4%
Net Revenue £m Volume Price / Mix LFL(1) Net M&A FX IFRS
YTD 2025 1,390 -3.1% -2.9% -6.0% +1.0% -4.0% -9.0%
Essential Home
· Net revenue declined -4.9% on a LFL basis to £479m in the
quarter, reflecting a volume growth of +0.6% and a price / mix impact
of -5.5%.
· Essential Home's European business is delivering as expected,
however, performance continues to be significantly impacted by a weak Brazil
pest category as it laps the prior season and softness in the U.S. Air Care
category.
· For 2025 YTD Essential Home net revenue declined -6.0% on a LFL
basis.
Further information
Presentation and Q&A for investors and analysts
We will be hosting a live webcast followed by a Q&A session for analysts
and investors at 08:30 (BST) on Wednesday 22 October 2025 at
https://www.reckitt.com/investors/results-and-presentations/
(https://www.reckitt.com/investors/results-and-presentations/)
To participate in the Q&A, dial in details are as follows:
United Kingdom: (020) 3481 4247
United States: (646) 307-1963
Other locations: +1 (646) 307-1963
Conference access code: 89743
Analysts and investors wanting to participate in the Q&A can do so via the
webcast or on the conference call using the instructions above.
For enquiries contact:
Investors: Nick Ashworth
+44 (0)7408 812350
Jon Bone
+44 (0)7408 811493
Media: Martinne Geller
+44 (0)7408 801216
Charlie Armitstead (FTI
Consulting)
+44 (0)7703 330269
Cautionary note concerning forward-looking statements
This announcement contains statements with respect to the financial condition,
results of operations and business of Reckitt Benckiser Group plc and the
Reckitt group of companies (the "Group") and certain of the plans and
objectives of the Group that are forward-looking statements. Words such as
''intends', 'targets', or the negative of these terms and other similar
expressions of future performance or results, and their negatives, are
intended to identify such forward-looking statements. In particular, all
statements that express forecasts, expectations and projections with respect
to future matters, including targets for net revenue, operating margin and
cost efficiency, are forward-looking statements. Such statements are not
historical facts, nor are they guarantees of future performance.
By their nature, forward-looking statements involve risk and uncertainty
because they relate to events and depend on circumstances that will occur in
the future. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied by these
forward-looking statements, including many factors outside the Group's
control. Among other risks and uncertainties, the material or principal
factors which could cause actual results to differ materially are: the general
economic, business, political, geopolitical and social conditions in the key
markets in which the Group operates; the Group's ability to innovate and
remain competitive; the Group's investment choices in its portfolio
management; the ability of the Group to address existing and emerging
environmental and social risks and opportunities; the ability of the Group to
manage regulatory, tax and legal matters, including changes thereto; the
reliability of the Group's technological infrastructure or that of third
parties on which the Group relies including the risk of cyber-attack;
interruptions in the Group's supply chain and disruptions to its production
facilities; economic volatility including increases in tariffs and the cost of
labour, raw materials and commodities; the execution of acquisitions,
divestitures and business transformation projects; product safety and quality,
and the reputation of the Group's global brands; and the recruitment and
retention of key management.
These forward-looking statements speak only as of the date of this
announcement. Except as required by any applicable law or regulation, the
Group expressly disclaims any obligation or undertaking to release publicly
any updates or revisions to any forward-looking statements contained herein to
reflect any change in the Group's expectations with regard thereto or any
change in events, conditions or circumstances on which any such statement is
based.
LEI: 5493003JFSMOJG48V108
APPENDIX - ALTERNATIVE PERFORMANCE MEASURES
The financial information included in this half year report is prepared in
accordance with International Financial Reporting Standards (IFRS) as well as
information presented on an adjusted (non-IFRS) basis.
Financial information presented on an adjusted basis excludes certain cash and
non-cash items. These items have a pattern of recognition that is largely
uncorrelated with the trading performance of the business. Management reviews
the business on this basis for the purpose of making operating decisions and
showing these adjusted measures in addition to the IFRS measures provides
useful additional information on trading performance to the users of the
financial statements. These adjusted measures should not be considered in
isolation from, substitutes for, or superior to the financial measures
prepared in accordance with IFRS.
Defintions:
Like-for-Like (LFL): Net revenue growth or decline at constant exchange rates
excluding the impact of acquisitions, disposals and discontinued operations.
Disposals include low margin manufacturing revenues which are agreed at the
time of sale of a brand or business. Completed disposals are excluded from LFL
revenue growth for the entirety of the current and prior years. Acquisitions
are included in LFL revenue growth twelve months after the completion of the
relevant acquisition. LFL growth also excludes countries with annual inflation
greater than 100% (Venezuela and Argentina) in the current or preceding year.
Constant exchange rate (CER): Net revenue and profit growth or decline
adjusting the actual consolidated results such that the foreign currency
conversion uses the same exchange rates as were applied in the previous
financial year and excludes the effect of applying hyperinflation accounting
in the relevant subsidiaries.
Reconciliation of IFRS Net Revenue to Like for Like Net Revenue growth
For the nine months to 30 September
Net revenue Emerging Markets Europe North America Core Reckitt Essential Home Mead Johnson Group
£m £m £m £m £m £m
2024 IFRS (Restated)(1) 2,912 2,621 1,970 7,503 1,527 1,592 10,622
M&A -12 -5 0 -17 0 -14 -31
Exchange and hyperinflation -25 -20 -4 -49 -50 -10 -109
2024 Like-for-like 2,875 2,596 1,966 7,437 1,477 1,568 10,482
2025 IFRS 3,159 2,554 1,896 7,609 1,390 1,592 10,591
M&A 0 0 0 0 0 -16 -16
Exchange and hyperinflation 111 33 57 201 -1 54 254
2025 Like-for-like 3,270 2,587 1,953 7,810 1,389 1,630 10,829
Like-for-like growth 13.7% -0.3% -0.7% 5.0% -6.0% 4.0% 3.3%
For the nine months to 30 September
Net revenue Self Care Germ Protection Household Care Intimate Wellness Core Reckitt
£m £m £m £m £m
2024 IFRS (Restated)(2) 2,470 2,319 1,668 1,046 7,503
M&A -12 0 0 -5 -17
Exchange and hyperinflation -14 -11 -17 -7 -49
2024 Like-for-like 2,444 2,308 1,651 1,034 7,437
2025 IFRS 2,412 2,414 1,634 1,149 7,609
M&A 0 0 0 0 0
Exchange and hyperinflation 52 87 37 25 201
2025 Like-for-like 2,464 2,501 1,671 1,174 7,810
Like-for-like growth 0.8% 8.4% 1.2% 13.5% 5.0%
( )
(1) In 2025, Reckitt has transferred some globally managed export businesses
previously reported within Reckitt Core Europe to be locally managed (within
Reckitt Core and Essential Home). 2024 comparatives have been restated
accordingly.
(2) Updated from results issued on 6 March 2025, for certain products that are
being managed as part of germ protection rather than household portfolio
For the quarter to 30 September
Net revenue Emerging Markets Europe North America Core Reckitt Essential Home Mead Johnson Group
£m £m £m £m £m £m
2024 IFRS (Restated)(1) 966 857 675 2,498 512 445 3,455
M&A 0 -2 0 -2 0 -7 -9
Exchange and hyperinflation 15 4 9 28 -6 12 34
2024 Like-for-like 981 859 684 2,524 506 450 3,480
2025 IFRS 1,080 865 658 2,603 479 529 3,611
M&A 0 0 0 0 0 -4 -4
Exchange and hyperinflation 53 1 35 89 2 24 115
2025 Like-for-like 1,133 866 693 2,692 481 549 3,722
Like-for-like growth 15.5% 0.8% 1.3% 6.7% -4.9% 22.0% 7.0%
(1) In 2025, Reckitt has transferred some globally managed export businesses
previously reported within Reckitt Core Europe to be locally managed (within
Reckitt Core and Essential Home). 2024 comparatives have been restated
accordingly.
For the quarter to 30 September
Net revenue Self Care Germ Protection Household Care Intimate Wellness Core Reckitt
£m £m £m £m £m
2024 IFRS (Restated)(2) 827 801 531 339 2,498
M&A 0 0 0 -2 -2
Exchange and hyperinflation 8 7 10 3 28
2024 Like-for-like 835 808 541 340 2,524
2025 IFRS 859 838 531 375 2,603
M&A 0 0 0 0 0
Exchange and hyperinflation 23 44 11 11 89
2025 Like-for-like 882 882 542 386 2,692
Like-for-like growth 5.6% 9.2% 0.2% 13.5% 6.7%
(2) Updated from results issued on 6 March 2025, for certain products that are
being managed as part of germ protection rather than household portfolio.
Reconciliation of like-for-like net revenue excluding seasonal OTC brands
For the nine months to 30 Sept
For the quarter to 30 Sept
Net revenue Self Care Core Reckitt Self Care Core Reckitt
£m £m £m £m
2024 Like-for-like 2,444 7,437 835 2,524
2024 seasonal OTC 971 971 355 355
2024 LFL ex. seasonal OTC 1,473 6,466 480 2,169
2025 Like-for-like 2,464 7,810 882 2,692
2025 seasonal OTC 895 895 343 343
2025 LFL ex. seasonal OTC 1,569 6,915 539 2,349
2025 Like-for-like growth 0.8% 5.0% 5.6% 6.7%
2025 LFL growth ex seasonal OTC 6.5% 6.9% 12.3% 8.3%
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END TSTMBBPTMTJTBBA
Copyright 2019 Regulatory News Service, all rights reservedRecent news on Reckitt Benckiser
See all newsREG - Reckitt Benckiser Gp - Transaction in Own Shares
AnnouncementREG - Reckitt Benckiser Gp - Transaction in Own Shares
AnnouncementREG - Reckitt Benckiser Gp - Commencement of Second Tranche of Share Buyback
AnnouncementREG - Reckitt Benckiser Gp - Transaction in Own Shares
AnnouncementREG - Reckitt Benckiser Gp - Reckitt Q3 2025 Trading Update
Announcement